Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK IND Pipeline 6
- Development stage
- Preclinical
- Lead developer
- BioCreatrix
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-NK IND Pipeline 6 is an investigational chimeric antigen receptor (CAR) engineered natural killer (NK) cell therapy being developed by BioCreatrix in collaboration with CBiolab. The therapy involves engineering NK cells to express a tri-specific CAR that targets three unspecified tumor-anchoring antigens. This multi-antigen targeting strategy is intended to increase the precision of tumor cell recognition and reduce the likelihood of immune evasion through antigen loss. The program is currently in the IND-enabling phase for the treatment of various cancers, leveraging the innate cytotoxicity of NK cells enhanced by targeted CAR engineering.
- Other names
- BioCreatrix CAR-NK cell therapy
Beyond the preview
Go deeper on CAR-NK IND Pipeline 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK IND Pipeline 6.